JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2004; 43:1534-1541, doi:10.1016/j.jacc.2003.12.040
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gattis, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gattis, W. A.

Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure

Results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial

Wendy A. Gattis, PharmD*, Christopher M. O'Connor, MD, FACC*, Dianne S. Gallup, MS*, Vic Hasselblad, PhD*, Mihai Gheorghiade, MD, FACC{dagger},* IMPACT-HF Investigators and Coordinators

* Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
{dagger} Division of Cardiology, Northwestern University/Feinberg School of Medicine, Chicago, Illinois, USA



View larger version (39K):

[in a new window]
  		Figure 1 Study outline. Patients with reactive airway disease were excluded per protocol, but patients with chronic obstructive pulmonary disease were allowed. The investigator made the determination of pulmonary disease too severe for the patient to be enrolled. AV = atrioventricular; EF = ejection fraction; HF = heart failure; NYHA = New York Heart Association.

 


View larger version (15K):

[in a new window]
  		Figure 2 (A) Kaplan-Meier curve depicting time to death + rehospitalization. (B) Kaplan-Meier curve depicting time to death, recurrent hospitalization, unscheduled visit for heart failure, ≥50% increase in oral diuretic therapy, addition of new oral diuretic therapy excluding spironolactone, or any intravenous therapy with diuretics, inotropes, inodilators, or other vasoactive agents within 60 days post-randomization. Solid lines = predischarge carvedilol initiation group; dashed lines = physician-discretion postdischarge initiation group. HR = hazard ratio.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.